Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
IPO Year: 2021
Exchange: NASDAQ
Website: reneopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2023 | Outperform → Market Perform | Leerink Partners | |
| 12/15/2023 | Buy → Hold | Jefferies | |
| 12/15/2023 | $30.00 → $1.50 | Buy → Neutral | H.C. Wainwright |
| 12/14/2023 | Buy → Neutral | Ladenburg Thalmann | |
| 12/14/2023 | $23.00 → $1.45 | Buy → Underperform | BofA Securities |
| 12/14/2023 | Outperform → Mkt Perform | William Blair | |
| 12/14/2023 | $28.00 → $3.00 | Outperform → Neutral | Robert W. Baird |
| 12/14/2023 | $25.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 11/15/2023 | $35.54 | Outperform | William Blair |
| 8/28/2023 | $30.00 | Buy | H.C. Wainwright |